195 related articles for article (PubMed ID: 9789122)
21. Melatonin as a new possible anti-inflammatory agent.
Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
[TBL] [Abstract][Full Text] [Related]
22. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Lissoni P; Barni S; Tancini G; Rovelli F; Ardizzoia A; Conti A; Maestroni GJ
Oncology; 1993; 50(6):399-402. PubMed ID: 8233281
[TBL] [Abstract][Full Text] [Related]
23. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
Brackowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S; Tancini G; Maestroni GJ
J Biol Regul Homeost Agents; 1994; 8(3):77-80. PubMed ID: 7754792
[TBL] [Abstract][Full Text] [Related]
24. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
Lissoni P; Barni S; Rovelli F; Brivio F; Ardizzoia A; Tancini G; Conti A; Maestroni GJ
Eur J Cancer; 1993; 29A(2):185-9. PubMed ID: 8422280
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
Lissoni P; Barni S; Cazzaniga M; Ardizzoia A; Rovelli F; Brivio F; Tancini G
Oncology; 1994; 51(4):344-7. PubMed ID: 8208518
[TBL] [Abstract][Full Text] [Related]
26. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.
Lissoni P; Tancini G; Barni S; Paolorossi F; Ardizzoia A; Conti A; Maestroni G
Support Care Cancer; 1997 Mar; 5(2):126-9. PubMed ID: 9069612
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
Lissoni P; Paolorossi F; Tancini G; Ardizzoia A; Barni S; Brivio F; Maestroni GJ; Chilelli M
Br J Cancer; 1996 Nov; 74(9):1466-8. PubMed ID: 8912546
[TBL] [Abstract][Full Text] [Related]
28. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.
Lissoni P; Meregalli S; Nosetto L; Barni S; Tancini G; Fossati V; Maestroni G
Oncology; 1996; 53(1):43-6. PubMed ID: 8570130
[TBL] [Abstract][Full Text] [Related]
29. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
[TBL] [Abstract][Full Text] [Related]
30. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
Lissoni P; Barni S; Fossati V; Ardizzoia A; Cazzaniga M; Tancini G; Frigerio F
Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
[TBL] [Abstract][Full Text] [Related]
31. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies.
Lissoni P; Barni S; Cattaneo G; Tancini G; Esposti G; Esposti D; Fraschini F
Oncology; 1991; 48(6):448-50. PubMed ID: 1749579
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
33. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
Lissoni P; Barni S; Ardizzoia A; Paolorossi F; Crispino S; Tancini G; Tisi E; Archili C; De Toma D; Pipino G
Oncology; 1992; 49(5):336-9. PubMed ID: 1382256
[TBL] [Abstract][Full Text] [Related]
34. A clinical-study of immunotherapy versus endocrine therapy versus chemotherapy in the treatment of advanced pancreatic adenocarcinoma.
Lissoni P; Ardizzoia A; Meregalli S; Barni S; Fossati V; Brivio F; Tancini G
Oncol Rep; 1994 Nov; 1(6):1277-80. PubMed ID: 21607530
[TBL] [Abstract][Full Text] [Related]
35. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
Lissoni P; Tisi E; Barni S; Ardizzoia A; Rovelli F; Rescaldani R; Ballabio D; Benenti C; Angeli M; Tancini G
Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Rovelli F; Cazzaniga M; Brivio F; Piperno A; Aldeghi R; Fossati D
Br J Cancer; 1993 Jun; 67(6):1404-7. PubMed ID: 8512825
[TBL] [Abstract][Full Text] [Related]
37. Pineal-opioid system interactions in the control of immunoinflammatory responses.
Lissoni P; Barni S; Tancini G; Fossati V; Frigerio F
Ann N Y Acad Sci; 1994 Nov; 741():191-6. PubMed ID: 7825805
[TBL] [Abstract][Full Text] [Related]
38. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
Lissoni P; Barni S; Meregalli S; Fossati V; Cazzaniga M; Esposti D; Tancini G
Br J Cancer; 1995 Apr; 71(4):854-6. PubMed ID: 7710954
[TBL] [Abstract][Full Text] [Related]
39. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
Lissoni P; Barni S; Tancini G; Brivio F; Tisi E; Zubelewicz B; Braczkowski R
J Biol Regul Homeost Agents; 1994; 8(4):126-9. PubMed ID: 7660855
[TBL] [Abstract][Full Text] [Related]
40. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
Lissoni P; Ardizzoia A; Tisi E; Rossini F; Barni S; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1993; 7(1):34-6. PubMed ID: 8346714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
